Equities analysts expect that Chimerix, Inc. (NASDAQ:CMRX) will post earnings of ($0.43) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.39). Chimerix reported earnings of ($0.37) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 16.2%. The firm is expected to report its next earnings results on Monday, November 6th.

On average, analysts expect that Chimerix will report full year earnings of ($1.68) per share for the current fiscal year, with EPS estimates ranging from ($1.87) to ($1.57). For the next financial year, analysts expect that the company will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.18) to ($1.49). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $1.28 million.

Several research firms recently weighed in on CMRX. ValuEngine lowered shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Wednesday, August 9th.

Chimerix (NASDAQ CMRX) remained flat at $5.00 during trading on Friday. The stock had a trading volume of 144,319 shares. The firm has a 50 day moving average of $4.72 and a 200 day moving average of $5.31. The firm’s market cap is $235.23 million. Chimerix has a 1-year low of $3.66 and a 1-year high of $6.64.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/10/zacks-analysts-anticipate-chimerix-inc-cmrx-will-announce-earnings-of-0-43-per-share.html.

Several large investors have recently made changes to their positions in the business. Teachers Advisors LLC increased its stake in shares of Chimerix by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 204 shares during the period. Bank of Montreal Can increased its stake in shares of Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 1,448 shares during the period. American International Group Inc. increased its stake in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 1,733 shares during the period. Nationwide Fund Advisors increased its stake in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 1,977 shares during the period. Finally, Alps Advisors Inc. increased its stake in shares of Chimerix by 5.5% in the second quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 2,178 shares during the period. Institutional investors own 67.53% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.